logo
Plus   Neg
Share
Email

Hikma Pharma Gets Rights To Commercialise 11 Of Chiesi's Products In Egypt

Hikma Pharmaceuticals PLC (HIK.L) has reached an exclusive licensing and distribution agreement with Chiesi Farmaceutici, which provides Hikma with exclusive rights to commercialise 11 of Chiesi's products in Egypt. These specialty products are primarily in respiratory and neonatal therapeutic areas.

Hikma Pharma said the new agreement, which builds on the company's existing partnership with Chiesi in Morocco, adds a range of products to the Egyptian portfolio, including Foster, Foster Nexthaler, Trimbow and Curosurf.

Chiesi Farmaceutici is a research-focused international pharmaceutical Group, headquartered in Italy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT